151 related articles for article (PubMed ID: 29849184)
1. Engineered membrane protein antigens successfully induce antibodies against extracellular regions of claudin-5.
Hashimoto Y; Zhou W; Hamauchi K; Shirakura K; Doi T; Yagi K; Sawasaki T; Okada Y; Kondoh M; Takeda H
Sci Rep; 2018 May; 8(1):8383. PubMed ID: 29849184
[TBL] [Abstract][Full Text] [Related]
2. Claudin-5-Binders Enhance Permeation of Solutes across the Blood-Brain Barrier in a Mammalian Model.
Hashimoto Y; Shirakura K; Okada Y; Takeda H; Endo K; Tamura M; Watari A; Sadamura Y; Sawasaki T; Doi T; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2017 Nov; 363(2):275-283. PubMed ID: 28819070
[TBL] [Abstract][Full Text] [Related]
3. Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.
Li X; Iida M; Tada M; Watari A; Kawahigashi Y; Kimura Y; Yamashita T; Ishii-Watabe A; Uno T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):206-13. PubMed ID: 25118216
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2.
Hashimoto Y; Hata T; Tada M; Iida M; Watari A; Okada Y; Doi T; Kuniyasu H; Yagi K; Kondoh M
Eur J Pharm Sci; 2018 May; 117():161-167. PubMed ID: 29448044
[TBL] [Abstract][Full Text] [Related]
5. Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting.
Yang H; Park H; Lee YJ; Choi JY; Kim T; Rajasekaran N; Lee S; Song K; Hong S; Choi JS; Shim H; Kim YD; Hwang S; Choi YL; Shin YK
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31905631
[TBL] [Abstract][Full Text] [Related]
6. Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.
Hashimoto Y; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Ann N Y Acad Sci; 2017 Jun; 1397(1):5-16. PubMed ID: 28415141
[TBL] [Abstract][Full Text] [Related]
7. Anti-Claudin Antibodies as a Concept for Development of Claudin-Directed Drugs.
Hashimoto Y; Okada Y; Shirakura K; Tachibana K; Sawada M; Yagi K; Doi T; Kondoh M
J Pharmacol Exp Ther; 2019 Feb; 368(2):179-186. PubMed ID: 30530622
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.
Hashimoto Y; Tada M; Iida M; Nagase S; Hata T; Watari A; Okada Y; Doi T; Fukasawa M; Yagi K; Kondoh M
Biochem Biophys Res Commun; 2016 Aug; 477(1):91-95. PubMed ID: 27286708
[TBL] [Abstract][Full Text] [Related]
9. Claudin-1, -3, -4 and -7 gene expression analyses in canine prostate carcinoma and mammary tissue derived cell lines.
Hammer SC; Nagel S; Junginger J; Hewicker-Trautwein M; Wagner S; Heisterkamp A; Ngezahayo A; Nolte I; Murua Escobar H
Neoplasma; 2016; 63(2):231-8. PubMed ID: 26774145
[TBL] [Abstract][Full Text] [Related]
10. Molecular and structural transmembrane determinants critical for embedding claudin-5 into tight junctions reveal a distinct four-helix bundle arrangement.
Rossa J; Protze J; Kern C; Piontek A; Günzel D; Krause G; Piontek J
Biochem J; 2014 Nov; 464(1):49-60. PubMed ID: 25174580
[TBL] [Abstract][Full Text] [Related]
11. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders.
Fiorentino M; Sapone A; Senger S; Camhi SS; Kadzielski SM; Buie TM; Kelly DL; Cascella N; Fasano A
Mol Autism; 2016; 7():49. PubMed ID: 27957319
[TBL] [Abstract][Full Text] [Related]
12. Claudin-1 Binder Enhances Epidermal Permeability in a Human Keratinocyte Model.
Nakajima M; Nagase S; Iida M; Takeda S; Yamashita M; Watari A; Shirasago Y; Fukasawa M; Takeda H; Sawasaki T; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Sep; 354(3):440-7. PubMed ID: 26139628
[TBL] [Abstract][Full Text] [Related]
13. Generation of specific monoclonal antibodies against the extracellular loops of human claudin-3 by immunizing mice with target-expressing cells.
Ando H; Suzuki M; Kato-Nakano M; Kawamoto S; Misaka H; Kimoto N; Furuya A; Nakamura K
Biosci Biotechnol Biochem; 2015; 79(8):1272-9. PubMed ID: 25744656
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.
Hashimoto Y; Kawahigashi Y; Hata T; Li X; Watari A; Tada M; Ishii-Watabe A; Okada Y; Doi T; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Pharmacol Res Perspect; 2016 Oct; 4(5):e00266. PubMed ID: 27713828
[TBL] [Abstract][Full Text] [Related]
15. Polar and charged extracellular residues conserved among barrier-forming claudins contribute to tight junction strand formation.
Piontek A; Rossa J; Protze J; Wolburg H; Hempel C; Günzel D; Krause G; Piontek J
Ann N Y Acad Sci; 2017 Jun; 1397(1):143-156. PubMed ID: 28415153
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood-brain barrier permeability for drug delivery to the brain in a non-human primate.
Tachibana K; Hashimoto Y; Shirakura K; Okada Y; Hirayama R; Iwashita Y; Nishino I; Ago Y; Takeda H; Kuniyasu H; Kondoh M
J Control Release; 2021 Aug; 336():105-111. PubMed ID: 34118338
[TBL] [Abstract][Full Text] [Related]
17. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).
Boshuizen RS; Marsden C; Turkstra J; Rossant CJ; Slootstra J; Copley C; Schwamborn K
MAbs; 2014; 6(6):1415-24. PubMed ID: 25484047
[TBL] [Abstract][Full Text] [Related]
18. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues.
Studnicka GM; Soares S; Better M; Williams RE; Nadell R; Horwitz AH
Protein Eng; 1994 Jun; 7(6):805-14. PubMed ID: 7937712
[TBL] [Abstract][Full Text] [Related]
19. Immunization method for multi-pass membrane proteins using highly metastatic cell lines.
Satofuka H; Okabe Y; Takano Y; Utsugi T; Ohtsu M; Murakami Y
Biochem Biophys Res Commun; 2014 Jul; 450(1):99-104. PubMed ID: 24866236
[TBL] [Abstract][Full Text] [Related]
20. Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.
Rossant CJ; Carroll D; Huang L; Elvin J; Neal F; Walker E; Benschop JJ; Kim EE; Barry ST; Vaughan TJ
MAbs; 2014; 6(6):1425-38. PubMed ID: 25484064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
